The estimated Net Worth of Suneel Gupta is at least $9.96 Milione dollars as of 9 January 2024. Mr. Gupta owns over 5,000 units of Protagonist Therapeutics Inc stock worth over $8,625,076 and over the last 6 years he sold PTGX stock worth over $0. In addition, he makes $1,331,740 as Chief Development Officer at Protagonist Therapeutics Inc.
Suneel has made over 4 trades of the Protagonist Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of PTGX stock worth $36,900 on 9 January 2024.
The largest trade he's ever made was exercising 40,000 units of Protagonist Therapeutics Inc stock on 26 April 2022 worth over $295,200. On average, Suneel trades about 6,786 units every 107 days since 2019. As of 9 January 2024 he still owns at least 192,567 units of Protagonist Therapeutics Inc stock.
You can see the complete history of Mr. Gupta stock trades at the bottom of the page.
Suneel Gupta Ph.D. serves as Chief Development Officer of the Company. Dr. Gupta has served as the Company's Chief Development Officer since May 2019, and served as the Company's Executive Vice President of Clinical Pharmacology and Clinical Operations from January 2019 to May 2019. Prior to joining Protagonist, he was Chief Scientific Officer of Impax Pharmaceuticals from 2008 to January 2019. Prior to Impax, Dr. Gupta was Senior Vice President and Distinguished Research Fellow at Johnson & Johnson, where he led the early development from 2002 through 2008. Prior to Johnson & Johnson, he held positions at ALZA Corporation from 1989 through 2001, where he had increasing levels of responsibility until ultimately being promoted to Vice President of Clinical Pharmacology & Product Discovery. Dr. Gupta serves on the scientific advisory boards of several pharmaceutical companies. He received his Ph.D. in Pharmacokinetics from the University of Manchester, UK in 1987 and did a postdoctoral fellowship in Clinical Pharmacology at the University of California, San Francisco.
As the Chief Development Officer of Protagonist Therapeutics Inc, the total compensation of Suneel Gupta at Protagonist Therapeutics Inc is $1,331,740. There are 1 executives at Protagonist Therapeutics Inc getting paid more, with Dinesh Patel having the highest compensation of $1,948,340.
Suneel Gupta is 62, he's been the Chief Development Officer of Protagonist Therapeutics Inc since 2019. There are 11 older and 9 younger executives at Protagonist Therapeutics Inc. The oldest executive at Protagonist Therapeutics Inc is Dr. David Y. Liu, 71, who is the Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel..
Suneel's mailing address filed with the SEC is 7707 Gateway Blvd #140, Newark, CA 94560, USA.
Over the last 8 years, insiders at Protagonist Therapeutics Inc have traded over $11,629,969 worth of Protagonist Therapeutics Inc stock and bought 3,007,840 units worth $35,519,073 . The most active insiders traders include Capital Partners Gp, L.L.C...., & Johnson Johnson & Johnson... e X L.P.Canaan Partners X Llc.... On average, Protagonist Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,387,307. The most recent stock trade was executed by William D. Waddill on 24 July 2024, trading 8,000 units of PTGX stock currently worth $103,040.
protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist
Protagonist Therapeutics Inc executives and other stock owners filed with the SEC include: